Literature DB >> 7436509

Successful pregnancy in transfusion-dependent thalassaemia.

R M Thomas, A E Skalicka.   

Abstract

Successful pregnancy in a transfusion-dependent thalassaemic patient receiving subcutaneous desferrixaomine is reported. This is the first such case to be described.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7436509      PMCID： PMC1626796          DOI： 10.1136/adc.55.7.572

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  4 in total

1.  COMPARISON OF SIXTY-SIX PATIENTS WITH THALASSEMIA MAJOR AND THIRTEEN PATIENTS WITH THALASSEMIA INTERMEDIA: INCLUDING EVALUATIONS OF GROWTH, DEVELOPMENT, MATURATION AND PROGNOSIS.

Authors:  M E ERLANDSON; R BRILLIANT; C H SMITH
Journal:  Ann N Y Acad Sci       Date:  1964-10-07       Impact factor: 5.691

2.  Beneficial effects of transfusing a patient with nontransfusion-dependent thalassaemia major.

Authors:  N McIntosh
Journal:  Arch Dis Child       Date:  1976-06       Impact factor: 3.791

3.  Total management of thalassaemia major.

Authors:  B Modell
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

4.  Endocrine function in thalassemia major.

Authors:  V C Canale; P Steinherz; M New; M Erlandson
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691
  4 in total
  2 in total

1.  Assessment of the developmental toxicity of deferoxamine in mice.

Authors:  M A Bosque; J L Domingo; J Corbella
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

2.  The reproduction in women affected by cooley disease.

Authors:  Carlo Pafumi; Vito Leanza; Luana Coco; Stefania Vizzini; Lilliana Ciotta; Alessandra Messina; Gianluca Leanza; Giuseppe Zarbo; Alfio D'Agati; Marco Antonio Palumbo; Alessandra Iemmola; Ferdinando Antonio Gulino; Maria Cristina Teodoro; Matthew Attard; Alina Cristina Plesca; Catarina Soares; Nina Kouloubis; Mayada Chammas
Journal:  Hematol Rep       Date:  2011-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.